Choose a folder
Baseline glycaemic control in the DISCOVER population
We are pleased to announce that an article analysing glycaemic control in patients enrolled in the DISCOVER study titled ‘Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme’ has now been published in Diabetes, Obesity and Metabolism.1
The article describes the glycated haemoglobin (HbA1c) levels in patients enrolled in DISCOVER from 37 countries across six continents at the initiation of second-line therapy (baseline), and the clinical and socioeconomic factors that were found to be associated with poor glycaemic control (defined as HbA1c levels > 8.0%).
Overall, baseline HbA1c level data were available for 80.9% of the patients enrolled in the study, with substantial regional variation in the proportion of patients with recorded baseline HbA1c levels (across region range [ARR]: 57.5–98.2%). The overall mean HbA1c level among these patients was 8.3% (ARR: 7.9–8.7%; Figure 1). More than 50.0% of the patients had an HbA1c level ≥ 8.0%, and more than 25.0% of patients had an HbA1c level ≥ 9.0%. Factors associated with poor baseline glycaemic control included living in a lower-middle-income country (versus living in a high-income country), a longer duration of type 2 diabetes and a lower education level.
The full article is available to read and download here!
Figure 1. Mean baseline HbA1c level by DISCOVER study region.
1. Khunti K et al. Glycaemic control in patients with type 2 diabetes initiating second-line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab 2019; doi:10.1111/dom.13866.